This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Deborah L. Livornese On Friday, March 21, 2025, FDA announced that it was further delaying the effective date for the ACNU final rule until May 27, 2025. We wrote about the December 26, 2024 publication of the final rule (89 FR 105288) here. Originally, the Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) final rule was to become effective January 27, 2025.
Jeffrey Gudin, MD, faculty in the department of anesthesiology and pain management at the University of Miami, said topical analgesics are safer alternatives to systemic medications.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.
Stefanie Ferreri, PharmD, BCACP, FAPhA, discusses literature exploring OTC drugs, supplements, and devices used for non-prescription or self-care purposes.
Ravi Patel, PharmD, MBA, MS, lead innovation advisor in the School of Pharmacy at the University of Pittsburgh, discusses challenges with new technology and the future of artificial intelligence in pharmacy.
Darcy Aslett, PharmD, residency program director for PGY-1 community-based residency at St. Luke's Health System, discusses clinical services in pharmacies for underserved patients.
Pharmacy is heading toward a breaking point. The way weve been treated, the way our profession has been devaluedits not sustainable. By 2045, I believe we will either see a complete transformation or a collapse that forces change. And frankly, I dont think most pharmacists are prepared for whats coming. Over the past seven years, Ive watched countless pharmacists struggle under the weight of burnout, anxiety, and toxic workplaces.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s advantages in stroke prevention and weight loss vs SGLT2s superiority in heart failure, CV death reduction, and renal protection.
Corporate backsliding on climate and diversity policies mean this years annual meetings may be tough for some of the UKs biggest companies The leafy surroundings of Sunbury-on-Thames in Surrey will provide an unlikely backdrop for potentially one of the most explosive events of an intriguing shareholder meeting season, as corporate Britain grapples with a rapidly shifting geopolitical backdrop.
Modafinil (Provigil) is a stimulant type of medication that is most often utilized in narcolepsy. In my geriatric practice, I do see occasional off-label use to help stimulate energy in patients who are experiencing fatigue. I’ll outline my top 5 modafinil clinical pearls. Modafinil Clinical Pearls Polypharmacy is a problem in my geriatric patient population. […] The post Top 5 Modafinil Clinical Pearls appeared first on Med Ed 101.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content